<subsec_element><subsec_header></subsec_header><slide_intro></slide_intro><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide1.png</sec_img><sec_label>Slide 1.</sec_label><sec_caption></sec_caption><sec_txt><h3>Practical Considerations to Extend Treatment for VTE: What Every Clinician Needs to Know </h3></sec_txt><sec_alt_txt>Slide 1.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide2.png</sec_img><sec_label>Slide 2.</sec_label><sec_caption></sec_caption><sec_txt><h3> Panelists</h3></sec_txt><sec_alt_txt>Slide 2.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide3.png</sec_img><sec_label>Slide 3.</sec_label><sec_caption></sec_caption><sec_txt><h3>VTE: Acute, Long-Term, and Extended Treatment<sup type="ref">[1]</sup></h3><ul><li>	The acute phase is the first week after VTE event, and it is the most dangerous time for patients, with the highest risk of death </li><li>	The long-term phase is out to the 3-month point, during which data show that all patients require treatment</li><li>	At the 3-month point, the extended treatment phase, a number of factors come into play, which determine who requires treatment beyond this point</li></ul></sec_txt><sec_alt_txt>Slide 3.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide4.png</sec_img><sec_label>Slide 4.</sec_label><sec_caption></sec_caption><sec_txt><h3>Provoked VTE<sup type="ref">[2,3]</sup></h3><ul><li>	It is challenging to identify the patients who warrant extended treatment</li></ul></sec_txt><sec_alt_txt>Slide 4.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide5.png</sec_img><sec_label>Slide 5.</sec_label><sec_caption></sec_caption><sec_txt><h3>Unprovoked VTE<sup type="ref">[4,5]</sup></h3><ul><li>	What we have learned is that patients with unprovoked VTE also have a considerable risk of recurrence</li><li>	For many clinicians, it is not a driver that prompts continued extended prophylaxis, but in clinical practice, many of these patients have several factors that need to be taken into account</li><li>	For these patients, it is much more a challenge to assess the risk of recurrence and to consider extended secondary VTE prevention</li></ul></sec_txt><sec_alt_txt>Slide 5.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide6.png</sec_img><sec_label>Slide 6.</sec_label><sec_caption></sec_caption><sec_txt><h3> Men Are at Higher Risk of VTE Than Are Women <sup type="ref">[6,7]</sup></h3></sec_txt><sec_alt_txt>Slide 6.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide7.png</sec_img><sec_label>Slide 7.</sec_label><sec_caption></sec_caption><sec_txt><h3> HERDOO2 Rule<sup type="ref">[2]</sup></h3><ul><li>	The HERDOO2 rule selects a lower-risk group of women who will not need extended anticoagulation because their risk of recurrence is 3% or less</li><li>	Patients at a lower risk of recurrence are patients whose D-dimer is negative at the end of 3 or 6 months of anticoagulation and remains negative on serial testing</li></ul></sec_txt><sec_alt_txt>Slide 7.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide8.png</sec_img><sec_label>Slide 8.</sec_label><sec_caption></sec_caption><sec_txt><h3>  VTE Extension Trials: NOACs vs Placebo<sup type="ref">[8-10]</sup></h3><ul><li>	Risk of recurrence is lower regardless of the non-vitamin K antagonist oral anticoagulant (NOAC) vs placebo </li><li>	What is most important is that, even compared with placebo, the bleeding risk is no different with NOACs</li></ul></sec_txt><sec_alt_txt>Slide 8.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide9.png</sec_img><sec_label>Slide 9.</sec_label><sec_caption></sec_caption><sec_txt><h3>  Extending Anticoagulation<sup type="ref">[11]</sup></h3><ul><li>	In the past, patients were not protected due to fear of bleeding and managing VKAs </li><li>	NOACs are more convenient and provide safer anticoagulation, so the threshold for protecting patients against recurrent VTE has significantly decreased</li><li>	The patient's initial presentation, whether it is a pulmonary embolism (PE) or a deep venous thromboembolism (DVT), is a factor to be taken into account when deciding on extending treatment</li><li>	PEs are more likely to recur as PE, and the case-fatality rate of recurrent PE is higher than the potential hazards because of recurrent DVT<sup type="ref">[12]</sup></li></ul></sec_txt><sec_alt_txt>Slide 9.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide10.png</sec_img><sec_label>Slide 10.</sec_label><sec_caption></sec_caption><sec_txt><h3>Bleeding<sup type="ref">[13]</sup></h3><ul><li>	EINSTEIN CHOICE demonstrated the ability to modulate intensity of treatment for the extended treatment phase and is a useful tool for clinicians<sup type="ref">[14]</sup></li></ul></sec_txt><sec_alt_txt>Slide 10.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide11.png</sec_img><sec_label>Slide 11.</sec_label><sec_caption></sec_caption><sec_txt><h3>Aspirin: WARFASA and INSPIRE<sup type="ref">[15,16]</sup></h3></sec_txt><sec_alt_txt>Slide 11.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide12.png</sec_img><sec_label>Slide 12.</sec_label><sec_caption></sec_caption><sec_txt><h3>EINSTEIN CHOICE: Study Design<sup type="ref">[14]</sup></h3><ul><li>	Patients who received standard anticoagulation for 6 to 12 months were then randomized to 1 of 3 groups: aspirin 100 mg, rivaroxaban 10 mg once daily, or rivaroxaban 20 mg once daily</li></ul></sec_txt><sec_alt_txt>Slide 12.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide13.png</sec_img><sec_label>Slide 13.</sec_label><sec_caption></sec_caption><sec_txt><h3>EINSTEIN CHOICE: Primary Outcome -- Recurrent VTE<sup type="ref">[14]</sup></h3><ul><li>	Both doses of rivaroxaban were superior to low-dose aspirin</li><li>	Low-dose aspirin was not as effective as anticipated</li></ul></sec_txt><sec_alt_txt>Slide 13.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide14.png</sec_img><sec_label>Slide 14.</sec_label><sec_caption></sec_caption><sec_txt><h3>EINSTEIN CHOICE: Bleeding Outcomes<sup type="ref">[14]</sup></h3><ul><li>	There were similar rates of major bleeding among the 3 groups</li><li>	Rivaroxaban 20 mg is associated with a slightly increased risk of nonmajor bleeds, whereas there was no difference between the 10 mg dose and low-dose aspirin</li><li>	EINSTEIN CHOICE provides evidence for using the option of rivaroxaban 10 mg for secondary VTE prevention</li></ul></sec_txt><sec_alt_txt>Slide 14.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide15.png</sec_img><sec_label>Slide 15.</sec_label><sec_caption></sec_caption><sec_txt><h3> EINSTEIN CHOICE: Provoked, Unprovoked, and History of VTE<sup type="ref">[14]</sup></h3><ul><li>	Subgroup analyses showed that these effects were consistent regardless of whether the patient had a provoked VTE, an unprovoked VTE, or a recurrent VTE</li><li>	Bleeding risks remain similar among the groups</li><li>	Aspirin may be an option only for patients who cannot afford NOACs</li></ul></sec_txt><sec_alt_txt>Slide 15.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide16.png</sec_img><sec_label>Slide 16.</sec_label><sec_caption></sec_caption><sec_txt><h3> AMPLIFY-EXT<sup type="ref">[8]</sup></h3><ul><li>	There is a consistency across the class of factor Xa inhibitors</li></ul></sec_txt><sec_alt_txt>Slide 16.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide17.png</sec_img><sec_label>Slide 17.</sec_label><sec_caption></sec_caption><sec_txt><h3>NOACs in Prevention of Cancer-Associated VTE<sup type="ref">[17,18]</sup></h3></sec_txt><sec_alt_txt>Slide 17.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide18.png</sec_img><sec_label>Slide 18.</sec_label><sec_caption></sec_caption><sec_txt><h3>Adherence<sup type="ref">[19]</sup></h3></sec_txt><sec_alt_txt>Slide 18.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide19.png</sec_img><sec_label>Slide 19.</sec_label><sec_caption></sec_caption><sec_txt><h3>Timing of Doses</h3></sec_txt><sec_alt_txt>Slide 19.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide20.png</sec_img><sec_label>Slide 20.</sec_label><sec_caption></sec_caption><sec_txt><h3> Anticoagulation and Need for Antiplatelet Therapy<sup type="ref">[15,20,21]</sup></h3><ul><li>	Very high-risk patients with the clear indication to continue anticoagulation were not included In EINSTEIN CHOICE and AMPLIFY-EXT</li></ul></sec_txt><sec_alt_txt>Slide 20.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide21.png</sec_img><sec_label>Slide 21.</sec_label><sec_caption></sec_caption><sec_txt><h3>Summary</h3></sec_txt><sec_alt_txt>Slide 21.</sec_alt_txt><qna_form></qna_form></slide_grp><slide_grp><sec_img><?dctmLink?><?dctmEditor?>/webmd/professional_assets/medscape/images/content/article/901/602/Slide22.png</sec_img><sec_label>Slide 22.</sec_label><sec_caption></sec_caption><sec_txt><h3>Thank You</h3><em>This content has been condensed for improved clarity.</em></sec_txt><sec_alt_txt>Slide 22.</sec_alt_txt><qna_form></qna_form></slide_grp><qna_form></qna_form></subsec_element>